Location of Repository

Strategies for the Use of Poly(adenosine diphosphate ribose) Polymerase (PARP) Inhibitors in Cancer Therapy

By Thomas Helleday and Cecilia E. Ström


Treatments with Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors have offered patients carrying cancers with mutated BRCA1 or BRCA2 genes a new and in many cases effective option for disease control. There is potentially a large patient population that may also benefit from PARP inhibitor treatment, either in monotherapy or in combination with chemotherapy. Here, we describe the multifaceted role of PARP inhibitors and discuss which treatment options could potentially be useful to gain disease control without potentiating side effects

Topics: DNA repair, poly(ADP-ribose) polymerase, synthetic lethality, cancer, Biology (General), QH301-705.5, Science, Q, DOAJ:Biology, DOAJ:Biology and Life Sciences, Microbiology, QR1-502
Publisher: MDPI AG
Year: 2012
DOI identifier: 10.3390/biom2040635
OAI identifier: oai:doaj.org/article:30eb83330ce548e1b1df793db7fe60d0
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://doaj.org/toc/2218-273X (external link)
  • http://www.mdpi.com/2218-273X/... (external link)
  • https://doaj.org/article/30eb8... (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.